Prostate Cancer Clinical Trials in Michigan

Showing 181-200 of 288 trials

A Registry for Hereditary Cancer Risk Assessment and Genetic Testing

NCT04015102

This prospective registry will evaluate the feasibility and impact of implementing standard cancer family history review and guideline-aligned genetic testing for men diagnosed with Prostate Cancer in community urology practices nationwide.

Prostate Cancer

Myriad Genetic Laboratories, Inc.255 participantsStarted Mar 2019

Little Rock, Arkansas, United States • Fresno, California, United States • Merrillville, Indiana, United States +7 more locations

COMPLETEDPhase 283 miles

A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

NCT02384382

The purpose of this study is to evaluate 18F-sodium fluoride positron-emission tomography / computed tomography (18F-NaF PET/CT) imaging as a method for determining treatment response in metastatic bone lesions in patients who are receiving enzalutamide for castration-resistant prostate cancer.

Prostate Carcinoma Metastatic to the BoneCastration Resistant Prostate Cancer

Pfizer23 participantsStarted Nov 2015

Detroit, Michigan, United States • Farmington Hills, Michigan, United States • New Brunswick, New Jersey, United States +2 more locations

COMPLETEDPhase 283 miles

Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy

NCT00428714

The purpose is to see how quickly two different types of prostate cancer participants respond when taking enzastaurin. Cohort 1 - asymptomatic participants with androgen-independent prostate-specific antigen (PSA)-progressive disease without clinical or radiographic evidence of metastatic disease. Cohort 2 - participants with androgen-independent metastatic prostate cancer (documented bone or soft tissue metastases) with rising PSA, clinical, radiographic disease progression following one prior docetaxel-based regimen

Prostate Cancer

Eli Lilly and Company73 participantsStarted Jan 2007

Los Angeles, California, United States • Stanford, California, United States • New Haven, Connecticut, United States +8 more locations

A Registry for Hereditary Cancer Risk Assessment and Genetic Testing

A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy

Prostate Cancer Trials in Other Cities

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

Prostate Cancer Intervention Versus Observation Trial (PIVOT)

Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer

Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer

Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Analyses of Human Samples Collected in Clinical Trials

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF

An Exercise Trial and Economic Analysis in Men With Prostate Cancer

Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Genetic Analysis of Hereditary Prostate Cancer

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Other Conditions in Michigan